Key Finding: JSPR is a highly speculative micro-cap clinical-stage biotech (~$18M market cap) with no approved products, significant cash burn, and recent strategic review announcement amid funding challenges; the stock is extremely volatile with limited analyst coverage and high execution risk.
Current Stock Price (as of ~July 14, 2026 market data)
Previous Close: $0.6079
Day Range: $0.6033 – $0.7599
52-Week Range: $0.3150 – $3.5300
Market Cap: ~$19.8M
Fact: Price fluctuates rapidly (penny stock). Data snapshots from July 10–14, 2026 show intraday moves of 10–20%+.
Real-time price may differ significantly; check live quotes.
Links for more information:
Yahoo Finance •
Nasdaq •
Robinhood
Stock Performance & Company Financials
Stock Performance
| Metric | Value | Notes |
|---|
| YTD Return | +66.78% | Strong short-term rebound possible from lows, but from depressed base |
| 1-Year Return | -81.63% | Significant long-term decline |
| Beta (5Y) | 3.07 | Highly volatile vs market |
| Avg Volume (3mo) | 514K | — |
| Shares Outstanding | 28.01M | Post 1:10 reverse split in Jan 2024 |
Fact: Performance data from Yahoo Finance/MarketWatch as of mid-July 2026.
Company Financials (Latest Reported)
| Metric | Value (TTM / mrq) | Notes |
|---|
| Revenue (TTM) | $0 | Clinical-stage; no commercial products |
| Net Income (TTM) | -$55.73M | — |
| EPS (TTM) | -$2.58 | — |
| Cash & Equivalents (Mar 31, 2026) | $14.14M | Key runway metric |
| Total Debt | $757K | Low leverage |
| Book Value/Share | $0.12 | — |
| Operating Cash Flow (TTM) | -$68.87M | High burn rate |
Uncertainty flagged: Financials based on Q1 2026 report (May 14, 2026) and TTM aggregates. Q2/Q3 2026 results not yet available.
High cash burn and $14M cash position as of Mar 31 suggest limited runway without additional financing or strategic action.
Links:
Company IR •
Yahoo Key Statistics •
Yahoo Financials
Analyst Ratings
| Analyst / Firm | Rating | Target Price | Date | Notes |
|---|
| TD Cowen | Hold (Downgraded) | — | May 15, 2026 | — |
| Consensus (Limited) | Sparse coverage | Avg ~$9.17 (range $1.50–$20.00) | — | Targets appear outdated relative to current ~$0.60 price |
Fact: Very limited analyst coverage typical for micro-cap biotechs.
High target prices likely reflect pre-dilution or earlier clinical optimism; current price reflects execution/funding risks.
Links for more information:
Yahoo Analysts •
MarketBeat
Customers & Competitors
Customers
- Fact: None currently — clinical-stage company with no approved or commercialized products.
- Interpretation: Future potential customers would be patients with chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), or asthma, treated via allergists, dermatologists, and pulmonologists at hospitals/specialty clinics.
- Uncertainty: Commercialization is years away (if successful); depends on Phase 2/3 success, regulatory approval, and reimbursement.
Competitors
Direct competitors are other clinical-stage biotechs targeting mast cell/KIT pathways or urticaria/asthma indications. Broader peers in small-cap biotech.
| Company (Ticker) | Focus | Market Cap (approx.) | Comparison |
|---|
| INmune Bio (INMB) | Immunology / innate immunity | — | Similar micro-cap biotech risk profile |
| Gossamer Bio (GOSS) | Inflammatory diseases | — | Overlaps in respiratory/inflammatory space |
| Aligos Therapeutics (ALGS) | Immunology / liver | — | Pipeline-stage peer |
| Other peers | Actinium (ATNM), Vor Bio (VOR), etc. | Varies | Stem cell / hematology overlap (historical JSPR focus) |
Fact: Larger pharma (e.g., Novartis, Sanofi) have approved CSU therapies (e.g., Xolair); JSPR's briquilimab aims for differentiated KIT inhibition.
Competitive landscape dynamic; success depends on clinical differentiation and safety data.
Links:
MarketBeat Competitors •
Company Website
Company Overview & History
Fact: Jasper Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Redwood City, California (founded 2018, ~22 employees). Lead candidate: briquilimab, an aglycosylated monoclonal antibody targeting CD117 (KIT) to deplete mast cells for mast cell-driven diseases (CSU, CIndU, asthma).
History (Fact): Originally focused on safer hematopoietic stem cell transplantation and ex vivo gene therapy. Pivoted emphasis to mast cell diseases. Went public via SPAC (Amplitude Healthcare Acquisition). 1:10 reverse split Jan 2024. CEO: Jeet Mahal (appointed ~Jan 2026).
Links: IR Site • Corporate Site
Recent News (2026)
- June 1, 2026: Announced exploration of strategic alternatives (asset sales, licensing, collaborations, potential sale/merger) to maximize shareholder value. Likely response to cash position and clinical/funding needs.
- May 14, 2026: Reported Q1 2026 financials (cash $14.1M, net loss ~$1.2M in quarter per reports) and clinical update; refiled Phase 2b CSU protocol with FDA. Plans to start study in H2 2026 subject to funding.
- Earlier: Positive clinical data updates on briquilimab in CSU/CIndU; presentations at conferences.
Interpretation: Strategic review signals potential distress or pivot; typical for cash-strapped biotechs. High uncertainty around outcomes.
Links for more:
Company Press Releases •
Yahoo News
Data compiled from Yahoo Finance, Nasdaq, Company IR, MarketWatch, GlobeNewswire, and other public sources as of July 2026 tool crawls.
All financials, prices, and ratings are snapshots and subject to rapid change. This is not investment advice.
Limitations: No real-time data; clinical-stage risks (no revenue, high failure probability); sparse analyst coverage; strategic alternatives outcome unknown.